Uziębło-Życzkowska Beata, Krzesiński Paweł, Jurek Agnieszka, Budnik Monika, Gorczyca Iwona, Kapłon-Cieślicka Agnieszka, Kiliszek Marek, Wójcik Agnieszka, Gawałko Monika, Jelonek Olga, Michalska Anna, Starzyk Katarzyna, Scisło Piotr, Kochanowski Janusz, Filipiak Krzysztof J, Wożakowska-Kapłon Beata, Opolski Grzegorz, Gielerak Grzegorz
Department of Cardiology and Internal Diseases, Military Institute of Medicine, Warsaw, Poland.
1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
Cardiovasc Diagn Ther. 2020 Aug;10(4):717-724. doi: 10.21037/cdt-20-151.
Oral anticoagulation therapy (OAT) prevents ischaemic incidents in patients with atrial fibrillation (AF). CHADS-VASc risk score of ≥2 points in men and ≥3 in women is a class I indication for OAT. OAT should also be considered as a prevention of thromboembolism in AF men with a CHADS-VASc score of 1 point and women with 2 points, but the class of recommendation is lower (IIa). This study aims to assess the occurrence of left atrial appendage thrombus (LAAT) and risk factors of its formation in patients with lower class recommendation to oral antiocoagulation treatment.
The study group consisted of 1,858 patients: 555 patients with class IIa indication to OAT (IIa group) and 1,303 patients with class I indication as a control group (I group). Patients were admitted to three cardiology departments. All subjects underwent transoesophageal echocardiography.
The incidence of LAAT was comparable in both IIa and I group: LAAT was confirmed in 30 (5.4%) subjects of IIa group and in 77 (5.9%) of I group. The prevalence of LAAT in IIa group was higher on treatment with VKAs (in comparison to NOACs) (8.4% 3.4%, P=0.010), and lower in case of paroxysmal AF (in comparison to non-paroxysmal AF) (2.4% 9.8%, P=0.0002). Multivariate logistic regression revealed the following variables as the independent predictors of LAAT in IIa group: treatment with VKAs (OR 2.99, 95% CI: 1.33-6.69; P=0.007), paroxysmal AF (OR 0.26, 95% CI: 0.11-0.62; P=0.002) and eGFR <60 mL/min/1.73 m (OR 3.19, 95% CI: 1.42-7.16; P=0.005).
The prevalence of LAAT in AF patients with lower class (IIa) recommendation to anticoagulants was comparable to higher (I). Treatment with VKAs, along with non-paroxysmal type of AF and eGFR <60 mL/min/1.72 m were identified as the strongest predictors of LAAT in IIa group.
口服抗凝治疗(OAT)可预防心房颤动(AF)患者发生缺血性事件。男性CHADS-VASc风险评分≥2分且女性≥3分是OAT的I类适应证。对于CHADS-VASc评分为1分的AF男性患者和2分的女性患者,OAT也应被视为预防血栓栓塞的措施,但推荐等级较低(IIa类)。本研究旨在评估口服抗凝治疗推荐等级较低的患者左心耳血栓(LAAT)的发生率及其形成的危险因素。
研究组由1858例患者组成:555例有OAT IIa类适应证的患者(IIa组)和1303例有I类适应证的患者作为对照组(I组)。患者被收治于三个心内科。所有受试者均接受经食管超声心动图检查。
IIa组和I组LAAT的发生率相当:IIa组30例(5.4%)受试者和I组77例(5.9%)受试者确诊有LAAT。IIa组中使用维生素K拮抗剂(VKA)治疗时LAAT的患病率较高(与非维生素K拮抗剂类口服抗凝药[NOACs]相比)(8.4%对3.4%,P = 0.010),而阵发性AF患者中LAAT的患病率较低(与非阵发性AF相比)(2.4%对9.8%,P = 0.0002)。多因素逻辑回归显示,以下变量是IIa组LAAT的独立预测因素:使用VKA治疗(比值比[OR]2.99,95%置信区间[CI]:1.33 - 6.69;P = 0.007)、阵发性AF(OR 0.26,95%CI:0.11 - 0.62;P = 0.002)和估算肾小球滤过率(eGFR)<60 mL/min/1.73 m²(OR